Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


10 Items
Title  Creator  Group name  Publishing year 
Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer Jandu et al. EquipeJPP 2023-10
Comparison of prone and supine positioning for breast cancer radiotherapy using REQUITE data: dosimetry, acute and two years physician and patient-reported outcomes Vakaet et al. EquipeJPP 2023-09
Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study Heumann et al. EquipeJPP 2023-01
Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer Kerns et al. EquipeJPP 2022-03
Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort Webb et al. EquipeJPP 2022-10
The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study van der Weijst et al. EquipeJPP 2022-11
Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study) Van der Weijst et al. EquipeJPP 2022-04
High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer Joseph et al. EquipeJPP 2022
External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort Rattay et al. EquipeJPP 2020
REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer Seibold et al. EquipeAP May 27, 2019
10 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés